Skip to main content
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
Published Web Location
https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa362/5819607?redirectedFrom=fulltextNo data is associated with this publication.
Abstract
To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.